Changing the way we look at cancer.
Cynvenio Biosystems is dedicated to the development and commercialization of highly sensitive cell isolation technologies for cancer diagnostics, drug development and biomedical research.
The new LiquidBiopsy® platform is a high performance rare cell isolation instrument designed to recover Circulating Tumor Cells (CTCs) from whole blood with the high purity & specificity necessary to support downstream molecular analysis such as PCR and next generation sequencing.
LiquidBiopsy sample collection kits simplify the patient sample collection and shipping process, requiring less than 10 minutes of training. Patient blood samples are FedExed to a LiquidBiopsy lab for processing, and require no refrigeration at any point in the process.
By unlocking vital molecular information from the DNA of individual patients using a simple blood draw, Cynvenio's LiquidBiopsy technology enables researchers and physicians to substantially improve their diagnostic and treatment decisions in real time, and for drug companies to genotypically select the subset of patients who will respond to targeted therapies.